Taylor Morrison Home
TMHC
Meta Platforms
META
D.R. Horton
DHI
4
Meritage Homes
MTH
5
Toll Brothers
TOL
US Stock MarketDetailed Quotes
BRTX Biorestorative Therapies
- 1.670
- +0.020+1.21%
Trading Mar 20 14:05 ET
11.56MMarket Cap-1.17P/E (TTM)
1.690High1.610Low19.49KVolume1.650Open1.650Pre Close32.08KTurnover0.45%Turnover RatioLossP/E (Static)6.92MShares2.55052wk High1.16P/B7.22MFloat Cap1.03052wk Low--Dividend TTM4.32MShs Float8.900Historical High--Div YieldTTM4.85%Amplitude1.030Historical Low1.645Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
Biorestorative Therapies Stock Forum
Maxim Group analyst Michael Okunewitch maintains $Biorestorative Therapies (BRTX.US)$ with a buy rating, and adjusts the target price from $6 to $8.
BioRestorative's FDA clearance for their BRTX-100 IND in chronic cervical discogenic pain represents a significant clinical and strategic expansion that could substantially enhance the company's market position in regenerative medicine for spinal conditions.
This development is particularly noteworthy for three key reasons:
BRTX-100 becomes the first and only stem cell therapy cleared for evaluation in cervical degenerative disc disease, esta...
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
First-Ever Stem Cell Treatment for Neck Pain Gets FDA Green Light - What Makes BRTX-100 Revolutionary?
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
Thursday, 27th February at 9:45 am
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –
– IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain –
– Company to host webcasted conference call today...
They have conference call tomorrow 10:30 am est
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
Wednesday, 26th February at 8:15 pm
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously ...
taking a starter position here
No comment yet